Rajagopal Ragaul, Yoztyurk Edzhem, Ravendran Kapilraj
Urology, East Sussex Healthcare NHS Trust, Eastbourne, GBR.
Urology, Gradscape, London, GBR.
Cureus. 2024 Oct 16;16(10):e71649. doi: 10.7759/cureus.71649. eCollection 2024 Oct.
Oncocytomas are referred to as benign kidney neoplasms. They primarily affect adults, with patients over 70 years old being the most affected. Renal oncocytomas (ROs) are frequently detected by excision, biopsy, or scan. Hematuria, flank pain, and a palpable mass are the traditional trio of symptoms. Oncocytomas appear as well-circumscribed, tan or mahogany-coloured masses with a central scar that is stellate. Histological features include well-circumscribed lesions, bland cytology, eosinophilic cytoplasm, regular nuclei with prominent central nucleoli, and nested architecture. ROs are rarely linked to an aggressive clinical course and have an excellent prognosis. There is proof that the disease can spread to the liver and bones. Some literature has also reported oncocytoma metastases to the lung and liver. This systematic review of the literature examines and evaluates the malignant potential of oncocytoma. The purpose of the study was to determine whether ROs can be diagnosed as a benign condition or if malignancy needs to be considered and investigated. Seventeen studies were analysed which had a total of 412 ROs. Four patients (one percent) died as a result of their illness. There was evidence of disease progression in every patient who passed away from their illness. Six patients (1.5%) experienced disease progression in total. Three hundred and seventeen patients (80%) underwent radical nephrectomy, while 81 patients (20%) underwent partial nephrectomy. Liver, bone, lung, lymphadenopathy, and local recurrence were among the metastasis sites. Perinephric fat invasion, renal sinus fat invasion, renal capsular invasion, and vascular invasion are characteristics of metastatic behavior that have been found. Despite this, the small number of patients who experienced disease progression and/or death as a result of ROs implies that aggressive malignant behavior is not always correlated with the presence of metastatic features or disease. Oncocytomas should be viewed as having a low potential for malignancy rather than as benign. Individuals who exhibit aggressive characteristics, such as vascular invasion and/or perinephric fat invasion, have an atypically good prognosis. Despite advancements in imaging and immunochemical techniques, it is indisputable that ROs, which were first classified as renal tumours in 1976, continue to pose a diagnostic challenge for multidisciplinary teams. There is considerable variation in practice across the globe due to difficulties in confirming ROs, especially when it comes to metastatic disease. There is even more variation in the management of follow-up care that follows. This will remain the MDT's current state until randomised controlled trials, long-term results, and a better comprehension of the behavior of this tumour are obtained.
嗜酸细胞瘤被认为是良性肾肿瘤。它们主要影响成年人,70岁以上的患者受影响最为严重。肾嗜酸细胞瘤(ROs)常通过切除、活检或扫描被检测到。血尿、侧腹痛和可触及的肿块是传统的三联征症状。嗜酸细胞瘤表现为边界清晰、棕褐色或红褐色的肿块,中央有星状瘢痕。组织学特征包括边界清晰的病变、温和的细胞学表现、嗜酸性细胞质、核规则且中央核仁突出,以及巢状结构。ROs很少与侵袭性临床病程相关,预后良好。有证据表明该疾病可扩散至肝脏和骨骼。一些文献也报道了嗜酸细胞瘤转移至肺和肝脏。本系统文献综述对嗜酸细胞瘤的恶性潜能进行了研究和评估。该研究的目的是确定ROs是否可被诊断为良性疾病,或者是否需要考虑并调查其恶性情况。分析了17项研究,共涉及412例ROs。4例患者(1%)因病死亡。每例死亡患者均有疾病进展的证据。总共有6例患者(1.5%)出现疾病进展。317例患者(80%)接受了根治性肾切除术,而81例患者(20%)接受了部分肾切除术。转移部位包括肝脏、骨骼、肺、淋巴结病和局部复发。已发现肾周脂肪浸润、肾窦脂肪浸润、肾包膜浸润和血管浸润是转移行为的特征。尽管如此,因ROs导致疾病进展和/或死亡的患者数量较少,这意味着侵袭性恶性行为并不总是与转移特征或疾病的存在相关。嗜酸细胞瘤应被视为恶性潜能较低而非良性。表现出侵袭性特征(如血管浸润和/或肾周脂肪浸润)的个体预后却出奇地好。尽管成像和免疫化学技术有所进步,但无可争议的是,1976年首次被归类为肾肿瘤的ROs,仍然给多学科团队带来诊断挑战。由于在确诊ROs方面存在困难,全球各地的实践存在很大差异,尤其是在转移性疾病方面。后续的随访管理差异更大。在获得随机对照试验、长期结果以及对该肿瘤行为的更好理解之前,这仍将是多学科团队当前面临的状况。